Sepsis Fells Another Contender
Agennix's Phase II/III Study Halted by Mortality Finding
By Nuala Moran
Friday, February 3, 2012
LONDON The challenging indication of severe sepsis has confounded yet another attempt to develop a registered treatment, with the curtailment of the Phase II/III trial of Agennix AG's talactoferrin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.